Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141271 · ClinicalTrials.gov registry record · Phase 3
A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 536
- Enrollment target
NCT00141271 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 536 participants.
The verdict
NCT00141271, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 536 participants
- Enrollment target
Study Summary
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.
Interventions
- DRUG Placebo
- DRUG Geodon (Ziprasidone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 536 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141271
The ClinicalTrials.gov registry entry for NCT00141271 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 536 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00141271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141271 about?
NCT00141271 is a clinical study titled "A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression". This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.
What is the current status of trial NCT00141271?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 536 participants. The study started on 2005-07. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00141271?
The interventions under investigation include: Placebo (DRUG), Geodon (Ziprasidone) (DRUG).
Who is sponsoring clinical trial NCT00141271?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.